See more : Grounded Lithium Corp. (GRD.V) Income Statement Analysis – Financial Results
Complete financial analysis of Gyre Therapeutics, Inc. (GYRE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gyre Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Dell Technologies Inc. (12DA.DE) Income Statement Analysis – Financial Results
- Jiangsu Yahong Meditech Co Ltd (688176.SS) Income Statement Analysis – Financial Results
- PP Capital – StockPick KL (PMIPCSPKLNO.CO) Income Statement Analysis – Financial Results
- Caravelle International Group (CACO) Income Statement Analysis – Financial Results
- Penyao Environmental Protection Co., Ltd. (300664.SZ) Income Statement Analysis – Financial Results
Gyre Therapeutics, Inc. (GYRE)
About Gyre Therapeutics, Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 113.45M | 794.00K | 7.34M | 20.95M | 0.00 | 6.00K | 1.02M | 399.00K | 1.75M | 275.00K | 3.63M | 57.86M | 97.64M | 85.71M | 25.06M | 20.09M | 11.58M | 27.54M | 1.18M | 3.74M | 2.46M | 2.29M | 1.70M |
| Cost of Revenue | 4.64M | 798.00K | 7.38M | 9.16M | 43.86M | 21.47M | 12.85M | 10.56M | 5.96M | 5.27M | 6.56M | 0.00 | 0.00 | 0.00 | 691.00K | 749.00K | 715.42K | 457.25K | 480.93K | 198.45K | 743.00K | 244.00K | 0.00 |
| Gross Profit | 108.81M | -4.00K | -42.00K | 11.79M | -43.86M | -21.47M | -11.83M | -10.16M | -4.21M | -4.99M | -2.93M | 57.86M | 97.64M | 85.71M | 24.37M | 19.34M | 10.86M | 27.08M | 698.98K | 3.54M | 1.72M | 2.04M | 1.70M |
| Gross Profit Ratio | 95.91% | -0.50% | -0.57% | 56.26% | 0.00% | -357,800.00% | -1,161.98% | -2,545.36% | -240.46% | -1,815.27% | -80.68% | 100.00% | 100.00% | 100.00% | 97.24% | 96.27% | 93.82% | 98.34% | 59.24% | 94.69% | 69.77% | 89.33% | 100.00% |
| Research & Development | 13.78M | 13.04M | 68.89M | 52.98M | 43.86M | 21.47M | 12.85M | 11.56M | 5.96M | 19.50M | 38.84M | 49.09M | 95.22M | 64.55M | 40.18M | 40.98M | 34.62M | 21.79M | 24.25M | 22.77M | 18.18M | 16.24M | 8.15M |
| General & Administrative | 14.66M | 17.37M | 18.96M | 16.18M | 13.42M | 12.35M | 9.99M | 9.26M | 9.59M | 10.17M | 12.01M | 13.19M | 12.17M | 8.05M | 8.17M | 6.50M | 8.01B | 5.70B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 61.16M | 54.24M | 44.65M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -8.00B | -5.69B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 75.82M | 17.37M | 18.96M | 16.18M | 13.42M | 12.35M | 9.99M | 9.26M | 9.59M | 10.17M | 12.01M | 13.19M | 12.17M | 8.05M | 8.17M | 6.50M | 8.01M | 5.70M | 6.39M | 5.16M | 3.60M | 4.14M | 2.30M |
| Other Expenses | 86.44M | -517.00K | -78.00K | 568.00K | -46.00K | 1.65M | 261.00K | 86.00K | 0.00 | 318.00K | 518.00K | 1.04M | 0.00 | 0.00 | 51.28M | 32.01M | 27.33B | 16.77B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 176.04M | 30.40M | 87.85M | 69.16M | 57.28M | 33.83M | 22.84M | 20.82M | 15.55M | 29.67M | 50.85M | 62.28M | 107.38M | 72.60M | 64.70M | 47.48M | 42.63M | 27.48M | 30.64M | 27.93M | 21.78M | 23.05M | 10.45M |
| Cost & Expenses | 180.68M | 31.20M | 95.23M | 78.32M | 57.28M | 33.83M | 22.84M | 20.82M | 15.55M | 29.67M | 50.85M | 62.28M | 107.38M | 72.60M | 65.39M | 48.23M | 43.35M | 27.94M | 31.12M | 28.13M | 22.52M | 23.29M | 10.45M |
| Interest Income | 0.00 | 537.00K | 39.00K | 1.13M | 2.10M | 3.77M | 261.00K | 3.47M | 518.00K | 585.00K | 784.00K | 1.07M | 1.22M | 1.46M | 1.05M | 2.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 717.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.48M | 23.00K | 53.00K | 86.00K | 132.00K | 153.00K | 217.00K | 251.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Depreciation & Amortization | 1.11M | 1.13M | 290.00K | 138.00K | 146.00K | 149.00K | 173.00K | 389.00K | 470.00K | 351.00K | 547.00K | 2.21M | 2.48M | 2.00M | 1.84M | 1.80M | 907.16K | 820.92K | 803.19K | 766.34K | 0.00 | 0.00 | 0.00 |
| EBITDA | 20.33M | 10.33M | -87.60M | -57.37M | -57.28M | -33.82M | -21.82M | -16.95M | -12.81M | -29.71M | -47.22M | -8.14M | -9.75M | 13.12M | -40.33M | -28.14M | -30.86M | 417.23K | -29.14M | -23.13M | -20.06M | -21.00M | -8.75M |
| EBITDA Ratio | 17.92% | -6,568.39% | -1,193.84% | -273.87% | 0.00% | -563,700.00% | -2,143.61% | -4,246.87% | -732.23% | -10,349.09% | -1,301.07% | -1.21% | -9.98% | 15.30% | -160.90% | -140.12% | -266.63% | 1.52% | -2,469.47% | -631.90% | -816.27% | -918.77% | -513.86% |
| Operating Income | -67.23M | -8.61M | -87.89M | -57.37M | -57.28M | -33.82M | -21.82M | -20.42M | -13.80M | -29.71M | -47.22M | -8.14M | -9.75M | 13.12M | -40.33M | -28.14M | -31.77M | -403.69K | -29.94M | -24.39M | -20.06M | -21.00M | -8.75M |
| Operating Income Ratio | -59.26% | -1,084.51% | -1,197.79% | -273.87% | 0.00% | -563,700.00% | -2,143.61% | -5,117.29% | -788.69% | -10,805.09% | -1,301.07% | -14.06% | -9.98% | 15.30% | -160.90% | -140.12% | -274.46% | -1.47% | -2,537.54% | -652.51% | -816.27% | -918.77% | -513.86% |
| Total Other Income/Expenses | -9.74M | 209.00K | -39.00K | 1.13M | 2.10M | 3.77M | 261.00K | 3.47M | -960.00K | 575.00K | 518.00K | 1.04M | 1.22M | 1.31M | 833.00K | 2.48M | 3.70B | -1.24B | 949.39K | 368.04K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -76.97M | -7.89M | -87.93M | -56.24M | -55.18M | -30.06M | -21.56M | -16.95M | -14.76M | -29.14M | -46.70M | -7.10M | -8.53M | 14.43M | -39.49M | -25.66M | -28.07B | -1.24B | 0.00 | -24.40M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -67.84% | -994.21% | -1,198.32% | -268.48% | 0.00% | -500,916.67% | -2,117.98% | -4,246.87% | -843.54% | -10,596.00% | -1,286.80% | -12.27% | -8.74% | 16.83% | -157.58% | -127.76% | -242,510.84% | -4,489.05% | 0.00% | -652.63% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 8.52M | 348.00K | -39.00K | -699.00K | -2.29M | 3.77M | -173.00K | 3.08M | 518.00K | 3.48M | 7.00K | -101.00K | -2.48M | 3.53M | -88.00K | -4.28M | -3.70M | -2.50M | -949.39K | -368.04K | 19.40M | 21.07M | 7.30M |
| Net Income | -92.93M | 2.30M | -87.93M | -55.54M | -52.89M | -30.06M | -21.56M | -16.95M | -14.76M | -32.62M | -46.71M | -7.00M | -8.53M | 10.90M | -39.40M | -25.66M | -28.07M | 2.10M | -28.99M | -24.03M | -19.40M | -21.07M | -7.30M |
| Net Income Ratio | -81.92% | 289.92% | -1,198.32% | -265.14% | 0.00% | -500,916.67% | -2,117.98% | -4,246.87% | -843.54% | -11,862.91% | -1,286.99% | -12.09% | -8.74% | 12.72% | -157.23% | -127.76% | -242.51% | 7.61% | -2,457.08% | -642.67% | -789.06% | -921.78% | -428.77% |
| EPS | -1.41 | 0.04 | -2.87 | -2.90 | -4.41 | -2.68 | -6.30 | -21.76 | -49.99 | -101.40 | -145.78 | -21.95 | -28.31 | 39.90 | -161.39 | -109.24 | -149.47 | -9.45 | -11.62K | -11.51K | -18.68K | -8.10K | -2.81K |
| EPS Diluted | -1.41 | 0.03 | -2.87 | -2.90 | -4.41 | -2.68 | -6.30 | -21.76 | -49.99 | -101.40 | -145.78 | -21.95 | -28.31 | 37.80 | -161.39 | -109.24 | -149.47 | -9.45 | -11.62K | -11.51K | -18.68K | -8.10K | -2.81K |
| Weighted Avg Shares Out | 65.83M | 76.74M | 30.64M | 19.18M | 12.00M | 11.21M | 3.42M | 778.78K | 295.27K | 321.72K | 320.39K | 318.82K | 301.31K | 271.84K | 244.16K | 234.90K | 187.82K | 129.48K | 2.50K | 2.09K | 1.04K | 2.60K | 2.60K |
| Weighted Avg Shares Out (Dil) | 65.83M | 75.69M | 30.64M | 19.18M | 12.00M | 11.21M | 3.42M | 778.78K | 295.27K | 321.72K | 320.39K | 318.82K | 301.31K | 287.15K | 244.16K | 234.90K | 187.82K | 129.48K | 2.50K | 2.09K | 1.04K | 2.60K | 2.60K |
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis in 2025 Commercial launch of avatrombopag...
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that the last patient in Gyre Pharmaceuticals'...
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that Han Ying, PhD, Chief Executive Officer, will...
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
Received NMPA approval of avatrombopag maleate tablets for the treatment of CLD-associated thrombocytopenia, expanding rare disease product lines Received IND approval from NMPA to evaluate F230 for the treatment of pulmonary arterial hypertension U.S. IND submission for F351 in MASH-associated...
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that Han Ying, PhD, Chief Executive Officer, will...
Gyre Therapeutics Announces China's NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
SAN DIEGO, July 02, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that China's National Medical Products Administration (“NMPA”) has...
Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a clinical-stage, self-sustainable biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ diseases, today announced the publication of the manuscript titled “Hydronidone induces apoptosis in...
Gyre Pharmaceuticals Receives IND Approval from China's NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a clinical-stage, self-sustainable biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ diseases, today announced that the Center for Drug Evaluation (“CDE”) of China's National...
Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
SAN DIEGO, May 28, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a clinical-stage, self-sustainable biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ diseases, today announced that it expects to be added to the small-cap Russell...
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Phase 3 clinical trial evaluating F351 for the treatment of CHB-associated liver fibrosis in the PRC remains on track with data anticipated by early 2025 U.S. IND submission to evaluate F351 for the treatment of NASH-associated liver fibrosis expected in...
Source: https://incomestatements.info
Category: Stock Reports